+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Fostamatinib"

From
Warm Autoimmune Hemolytic Anemia (WAIHA) - Pipeline Insight, 2020 - Product Thumbnail Image

Warm Autoimmune Hemolytic Anemia (WAIHA) - Pipeline Insight, 2020

  • Clinical Trials
  • September 2020
  • 70 Pages
  • Global
From
  • 2 Results (Page 1 of 1)
Loading Indicator

Fostamatinib is a medication used to treat immune disorders. It is a tyrosine kinase inhibitor, meaning it works by blocking certain proteins that are involved in the development of immune disorders. Fostamatinib is used to treat chronic immune thrombocytopenia, a condition in which the body does not produce enough platelets. It is also used to treat warm autoimmune hemolytic anemia, a condition in which the body's immune system attacks its own red blood cells. Fostamatinib is available in tablet form and is taken orally. Fostamatinib is a relatively new drug, having been approved by the US Food and Drug Administration in 2018. It is currently the only approved tyrosine kinase inhibitor for the treatment of immune disorders. As such, it has become an important treatment option for patients with these conditions. Several companies are involved in the Fostamatinib market. These include AstraZeneca, Rigel Pharmaceuticals, and Takeda Pharmaceuticals. AstraZeneca manufactures and markets the drug under the brand name Tavalisse. Rigel Pharmaceuticals is responsible for the development and commercialization of Fostamatinib. Takeda Pharmaceuticals is a global pharmaceutical company that markets the drug in Japan. Show Less Read more